Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fluorouracil + Mitomycin C |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent that interferes with DNA and RNA synthesis, thereby preventing cancer cell growth (PMID: 28520376). Adrucil (fluorouracil) is FDA-approved for use in patients with adenocarcinoma of the colon, rectum, breast, stomach, and pancreas (FDA.gov). |
| Mitomycin C | Mitozytrex | Chemotherapy - Alkylating 18 | Mitomycin C is an antibiotic alkylating agent, which cross-links DNA to prevent DNA synthesis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04929028 | Phase II | Capecitabine + Mitomycin C Nivolumab Fluorouracil + Mitomycin C | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Recruiting | USA | 0 |
| NCT03775265 | Phase III | Atezolizumab + Cisplatin + Mitomycin C Fluorouracil + Mitomycin C Atezolizumab + Gemcitabine + Mitomycin C Gemcitabine + Mitomycin C Atezolizumab + Fluorouracil + Mitomycin C Cisplatin + Mitomycin C | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
| NCT06770582 | Phase II | Fluorouracil + Mitomycin C Gemcitabine Pembrolizumab Cisplatin | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Recruiting | USA | 0 |
| NCT04216290 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | Active, not recruiting | USA | 0 |
| NCT04230759 | Phase II | Durvalumab + Fluorouracil + Mitomycin C Fluorouracil + Mitomycin C | Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE) | Active, not recruiting | DEU | CHE | AUT | 0 |